For the third consecutive month, Dupixent was named the top Rx and over-the-counter (OTC) brand by iSpot.tv.
According to the rankings of the top 10 brands, Dupixent had an impressions share of voice (SOV) of 5.07% and 2.6 billion impressions overall. The eczema and asthma treatment had an estimated national TV ad spend of $20 million and again found most of its success on ABC and ABC World News Tonight With David Muir.
Dupixent continues to be a reliable moneymaker for Sanofi and Regeneron, with sales growing 33% year-over-year, notching nearly $2.8 billion in Q2.
In addition to its three-month dominance, Dupixent was the top Rx and OTC brand in January and March as well.
Skyrizi finished in second place with an impressions SOV of 4.26% and 2.2 billion impressions supported by an estimated $23.2 million in national TV ad spend, the largest among the brands included in the top 10.
The Crohn’s disease, psoriasis and psoriatic arthritis treatment from Boehringer Ingelheim and AbbVie has been dueling with Dupixent for the top spot all year.
In the third slot was Rinvoq with an impressions SOV of 3.46% and 1.8 billion impressions total. The eczema, arthritis and ulcerative colitis (UC) treatment jumped up one spot and had an estimated national TV ad spend of $19.5 million last month.
Rounding out the top five was Claritin with an impressions SOV of 2.40% and 1.2 billion impressions and an estimated national TV ad spend of $4.2 million, along with Trelegy and its 2.11% impressions SOV and 1.1 billion impressions.
“Prescription and over-the-counter medications typically advertise more heavily during news and talk shows, and some have also been exploring popular syndicated sitcoms this summer,” iSpot’s chief marketing officer Cassandra Arora said in a statement. “With TV schedules in flux this fall, those programs may see increased audiences, creating opportunities for increased messaging reach as a result.”
On the back half of the list were Ubrelvy, Advil, Vraylar, Qulipta as well as America’s Best Contacts and Eyeglasses. Advil had the smallest estimated national TV ad spend among the top 10 brands with $2.7 million.
The monthly data from iSpot.tv was released shortly after it issued a report ranking the top 10 ‘new’ brands in terms of TV ad impressions. Pharma dominated the list thanks to Bayer’s Astrepo leading the way followed by the likes of Skyrizi, Bristol Myers Squibb’s Sotyktu and Eli Lilly’s diabetes drug Mounjaro.